F1000Prime » Article Recommendations » Oncology »

Oncology Agents Recommendations

To view Article Recommendations, you must have an active subscription.

If your access has expired, you can subscribe at $9.95 per month, the first month of your subscription will be free of charge.

If you think you should be able to access this content, please contact us.

New to F1000? See this week’s top article below for a free preview of a Recommendation.

Take the tour.

SECTION HEADS

David Kerr

Department of Clinical Pharmacology, University of Oxford, Oxford, UK
Gilberto Schwartsmann

CPG Clinica Medica da UFRGS, Hospital de Clinicas de Porto Alegre - UFRGS, Santa Cecília, Porto Alegre, Brazil

Section Topics

» Anti-angiogenic agents
» Anti-emetics and other drugs combating side effects
» Cancer gene therapies
» Cancer vaccines
» Cytokines
» Cytoxics
» Growth factors

» Hormonal agents
» Monoclonal antibodies
» New agents (phase I + II trials) and novel combination therapies
» Other antineoplastic agents
» Other supportive care agents
» Signal transduction inhibitors

LATEST RECOMMENDATION

This is a large randomized phase III trial; its aim was to show that intermittent androgen deprivation (ADT) was not inferior to continuous ADT in patients with metastatic hormone-sensitive prostate cancer. It failed to demonstrate...

Jean Pierre Droz and Helen Boyle, Center Léon-Bérard, France. F1000 Oncology

Score:

INDIVIDUAL SUBSCRIPTIONS

Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.

Start your personal subscription today.

Subscribe for $9.95/month

Take the tour.